Zhejiang Jiuzhou Pharmaceutical (SHA:603456) subsidiary Zhejiang Ruibo passed an on-site Current Good Manufacturing Practice inspection conducted by the US Food and Drug Administration.
The inspection covered quality systems, materials, production, packaging, labeling, equipment, and laboratory controls, according to a Thursday filing with the Shanghai bourse.
The inspection site was the active pharmaceutical ingredient base at 18 Nanyang 3rd Road, Linhai Park in China's Zhejiang province.
Shares of the drugmaker closed 1% higher Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.